张喆, 李玉琴, 施亚宁, 宿树兰, 范若颖, 尚尔鑫, 朱悦, 段金廒. 基于UPLC-Q-TOF-MS/MS及网络药理学探讨活络效灵丹治疗糖尿病周围神经病变的物质基础研究J. 药学学报, 2025, 60(4): 1124-1136. DOI: 10.16438/j.0513-4870.2024-1123
引用本文: 张喆, 李玉琴, 施亚宁, 宿树兰, 范若颖, 尚尔鑫, 朱悦, 段金廒. 基于UPLC-Q-TOF-MS/MS及网络药理学探讨活络效灵丹治疗糖尿病周围神经病变的物质基础研究J. 药学学报, 2025, 60(4): 1124-1136. DOI: 10.16438/j.0513-4870.2024-1123
ZHANG Zhe, LI Yu-qin, SHI Ya-ning, SU Shu-lan, FAN Ruo-ying, SHANG Er-xin, ZHU Yue, DUAN Jin-ao. Exploring the material basis of Huoluoxiaolingdan in the treatment of diabetic peripheral neuropathy based on UPLC-Q-TOF-MS/MS and network pharmacologyJ. Acta Pharmaceutica Sinica, 2025, 60(4): 1124-1136. DOI: 10.16438/j.0513-4870.2024-1123
Citation: ZHANG Zhe, LI Yu-qin, SHI Ya-ning, SU Shu-lan, FAN Ruo-ying, SHANG Er-xin, ZHU Yue, DUAN Jin-ao. Exploring the material basis of Huoluoxiaolingdan in the treatment of diabetic peripheral neuropathy based on UPLC-Q-TOF-MS/MS and network pharmacologyJ. Acta Pharmaceutica Sinica, 2025, 60(4): 1124-1136. DOI: 10.16438/j.0513-4870.2024-1123

基于UPLC-Q-TOF-MS/MS及网络药理学探讨活络效灵丹治疗糖尿病周围神经病变的物质基础研究

Exploring the material basis of Huoluoxiaolingdan in the treatment of diabetic peripheral neuropathy based on UPLC-Q-TOF-MS/MS and network pharmacology

  • 摘要: 本实验通过超高效液相色谱-四极杆-飞行时间串联质谱(UPLC-Q-TOF-MS/MS)、网络药理学探讨活络效灵丹治疗糖尿病周围神经病变(diabetic peripheral neuropathy, DPN) 的物质基础。利用UPLC-Q-TOF-MS/MS技术结合PeakViewTM 1.2软件、Molecule ProfilerTM软件分析活络效灵丹的体外成分及正常大鼠与高脂饲料喂养联合小剂量链脲佐菌素注射所致DPN大鼠的入血成分, 通过Swiss Target Prediction、GeneCards等数据库筛选成分对应靶点及疾病靶点, 利用Venny 2.1平台获得交集靶点, 导入STRING平台及Cytoscape 3.10.1软件构建蛋白互作网络及“成分-靶点”网络图分析其核心成分与核心靶点, 对核心靶点进行GO和KEGG富集分析。实验获得南京中医药大学实验动物伦理委员会批准(批准号: 202310A023)。结果共鉴定出活络效灵丹提取物83个化学成分, 包括丹参酮ⅡA等52个萜类、Z-藁本内酯等11个苯酞类、阿魏酸等15个有机酸类及4个香豆素类、1个酚类成分。在正常大鼠血浆中鉴定出15个原型成分与29个代谢产物, 在DPN大鼠血浆中鉴定出17个原型成分与32个代谢产物。网络药理学结果显示, 3-乙酰基-11-酮基-β-乳香酸、11-酮基-β-乳香酸等5个核心成分可能通过TNF、IL6等27个核心靶点, 调节AGE-RAGE、PI3K/Akt等信号通路发挥治疗DPN的作用。本研究通过UPLC-Q-TOF-MS/MS技术分析了活络效灵丹的体内外化学成分及主要化合物的裂解规律, 结合网络药理学分析其治疗DPN的核心成分, 为阐明活络效灵丹治疗DPN的功效物质基础及作用机制研究提供科学依据。

     

    Abstract: This study investigated the material basis of Huoluoxiaolingdan in treating diabetic peripheral neuropathy (DPN) through ultra performance liquid chromatography-quadrupole-time-of-flight mass spectrometry (UPLC-Q-TOF-MS/MS) and network pharmacology. UPLC-Q-TOF-MS/MS combined with PeakViewTM 1.2 software and Molecule ProfilerTM software were used to analyze the the chemical components of Huoluoxiaolingdan and blood-absorbed ingredients in normal rats and rats with DPN induced by high fat diet combined with low dose streptozotocin injection. Swiss Target Prediction database, GeneCards and other databases were used to search the corresponding targets of active ingredients and disease targets. The intersection targets were obtained using Venny 2.1 platform, which were then imported into the STRING platform and Cytoscape 3.10.1 software to construct the protein-protein interaction network and the "component-target" network relationship diagram, and the core components and core targets were analyzed. GO and KEGG pathway enrichment analysis of key targets were performed. All experiments were approved by the experimental Animal Ethics Committee from Nanjing University of Chinese Medicine (No. 202310A023). A total of 83 chemical components were identified, including 52 terpenoids such as tanshinone ⅡA, 11 phthalides such as Z-ligustilide, 15 organic acids such as ferulic acid, 4 coumarins and 1 phenol. Additionally, 15 prototype components and 29 metabolites were identified in normal rats' plasma, and 17 prototype components and 32 metabolites were identified in DPN rats' plasma. Network pharmacology results show that 5 core components such as 3-acetyl-11-keto-β-boswellic acid and 11-keto-β-boswellic acid may act through 27 core targets such as TNF and IL6 to regulate AGE-RAGE and PI3K/Akt and other signaling pathways so as to play a therapeutic role in treatment of DPN. The study efficiently analyzed the constituents in vitro and blood-absorbed ingredients of Huoluoxiaolingdan and the cracking regularity of the main compounds, and the core components of its treatment of DPN were analyzed in combination with network pharmacology, which can provide reference for further research of the pharmacodynamic substantial basis and mechanism of Huoluoxiaolingdan in the treatment of DPN.

     

/

返回文章
返回